2015 Publications
Highlights | 2016 | 2015 | 2014 | 2013 | 2012 | Archived
MIR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. EM Nilsson, KB Laursen, J Whitchurch, A McWilliam, N Odum, JL Persson, DM Heery, LJ Gudas and NP Mongan. (2015) Oncotarget 1-16.
Synthesis and intracellular redox cycling of natural quinones and their analogues and identification of indoleamine-2,3-dioxygenase (IDO) as potential target for anticancer activity. C. E. Blunt, C. Torcuk, Y. Liu, W. Lewis, D. Siegel, D. Ross and C. J. Moody, Angew. Chem. Int. Ed., 2015, 54, 8740-8745.
Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Rea D, Francis A, Hanby AM, Speirs V, Rakha E, Shaaban A, Chan S, Vinnicombe S, Ellis IO, Martin SG, Jones LJ, Berditchevski F. UK Inflammatory Breast Cancer Working group. Br J Cancer. 2015 Apr 28;112(9):1613-5.
Lymphovascular invasion: assessment and prognostic impact in melanoma and breast cancer. Thompson N, Storr S, Zhang S, Martin S. Histol Histopathol. 2015 Sep;30(9):1001-9.
Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication. Perry C, Soomro I, Kaye P, Hardy E, Parsons SL, Ragunath K, Lobo DN, Martin SG, Madhusudan S. Dis Esophagus. 2015 Apr;28(3):262-8.
An internal ribosome entry site in the 5' untranslated region of epidermal growth factor receptor allows hypoxic expression. Webb TE, Hughes A, Smalley DS, Spriggs KA. (2015) Oncogenesis Jan 26;4:e134. doi: 10.1038/oncsis.2014.43.
FKBPL: a marker of good prognosis in breast cancer. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirstrom K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Oncotarget 2015;6(14):12209-23.
The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.Modelska A, Turro E, Russell R, Beaton J, Sbarrato T, Spriggs K, Miller J, Gräf S, Provenzano E, Blows F, Pharoah P, Caldas C, Le Quesne J. (2015) Cell Death Dis. Jan 22;6:e1603. doi: 10.1038/cddis.2014.542.
Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Navani N, Nankivell M, Lawrence DR, Lock S, Makker H, Baldwin DR, Stephens RJ, Parmar MK, Spiro SG, Morris S and Janes SM. Lancet Respiratory Medicine 2015;http://dx.doi.org/10.1016/S2213-2600(15)00029-6.
Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit. Rich AL, Khakwani A, Free CM, Tata LJ, Stanley RA, Peake MD, Hubbard RB and Baldwin DR. QJM 2015 doi: 10.1093/qjmed/hcv052.
Reliable EGFR mutation testing in ultrasound guided supraclavicular lymph node fine needle aspirates: a cohort study with diagnostic performance analysis. Awwad A, Tiwari S, Sovani V, Baldwin DR, Kumaran M. BMJ Open Respiratory Research 2015 in press.
Barriers to uptake among high-risk individuals declining participation in lung cancer screening: A mixed-method analysis of the United Kingdom Lung Cancer Screening (UKLS) trial. Ali N, Lifford KJ, Carter B, McRonald F, Yadegarfar G, Baldwin DR, Weller D, Hansell DM, Duffy SW, Field JK and Brain K. BMJ Open 2015 in press.
Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients. Ravipati S, Baldwin DR, Barr HL, Fogarty AW and Barrett DA. Metabolomics 2015 DOI 10.1007/s11306-015-0811-x.
KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA. Br J Cancer. 2015 Jun 9;112(12):1929-37. doi: 10.1038/bjc.2015.165. Epub 2015 May 19.
Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Aleskandarany MA, Soria D, Green AR, Nolan C, Diez-Rodriguez M, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2015 Jun;151(2):325-33. doi: 10.1007/s10549-015-3406-3.
FKBPL: a marker of good prognosis in breast cancer. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Oncotarget. 2015 May 20;6(14):12209-23.
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, Behnke ML, Huang W, McKew JC, Chernoff J, Forrest WF, Haverty PM, Chin SF, Rakha EA,Green AR, Ellis IO, Caldas C, O'Brien T, Friedman LS, Koeppen H, Rudolph J, Hoeflich KP. Breast Cancer Res. 2015 Apr 23;17:59. doi: 10.1186/s13058-015-0564-5.
Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Abduljabbar R, Al-Kaabi MM, Negm OH, Jerjees D, Muftah AA, Mukherjee A, Lai CF, Buluwela L, Ali S, Tighe PJ, Green A, Ellis I, Rakha E. Breast Cancer Res Treat. 2015 Apr;150(3):511-22. doi: 10.1007/s10549-015-3348-9. Epub 2015 Mar 21.
Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green AR, Ali S, Rakha EA, Ellis IO. Breast Cancer Res Treat. 2015 Apr;150(2):335-46.
The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Jerjees DA, Negm OH, Alabdullah ML, Mirza S, Alkaabi M, Hameed MR, Abduljabbar R, Muftah A, Nolan CC, Green AR, Tighe PJ, Band V, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2015.
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR. Breast Cancer Res Treat. 2015 Feb;150(1):81-90.
Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Al-Kaabi MM, Alshareeda AT, Jerjees DA, Muftah AA, Green AR, Alsubhi NH, Nolan CC, Chan S, Cornford E, Madhusudan S, Ellis IO, Rakha EA. Br J Cancer. 2015 Mar 3;112(5):901-11. doi: 10.1038/bjc.2014.576. Epub 2015 Feb 17.
Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Moseley PM, Aleskandarany MA, Green AR, Ball G, Alshareeda AT, Rakha EA, Chan SY, Ellis IO, Madhusudan S. Mol Cancer Ther. 2015 Apr;14(4):1057-65.
Biological and clinical significance of PARP1 protein expression in breast cancer. Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2015 Jan;149(2):353-62.
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S. Mol Oncol. 2015 Mar;9(3):569-85. doi:
The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG. J Cancer Res Clin Oncol. 2015 Mar;141(3):505-14.
Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, Rakha EA, Green A, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S. Mol Oncol. 2015 Jan;9(1):204-17.
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G. (2015) Oncogene. Apr 16;34(16):2103-14.
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C. Mol Oncol. 2015 Jan;9(1):115-27.
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: Short, medium and long-term effects based on sequential biopsies. Agrawal A, Robertson JF, Cheung KL, Gutteridge E, Ellis IO, Nicholson RI, Gee JM. Int J Cancer. 2015 PMID: 26178788.
Pleomorphic adenoma-like tumour of the breast. Rakha EA, Aleskandarany MA, Samaka RM, Hodi Z, Lee AH, Ellis IO. Histopathology. 2015 PMID: 26096183.
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, Marchiò C, da Cruz Paula A, De Filippo MR, Martelotto LG, De Mattos-Arruda L, Edelweiss M, Jungbluth AA, Fusco N, Norton L, Weigelt B, Ellis IO, Reis-Filho JS. J Pathol. 2015 May 23. PMID: 26011570.
Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Rea D, Francis A, Hanby AM, Speirs V, Rakha E, Shaaban A, Chan S, Vinnicombe S, Ellis IO, Martin SG, Jones LJ, Berditchevski F; UK Inflammatory Breast Cancer Working group. Br J Cancer. 2015 Apr 28;112(9):1613-5.
National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. Rakha EA, Pigera M, Shaaban A, Shin SJ, D'Alfonso T, Ellis IO, Lee AH. J Clin Oncol. 2015 Apr 10;33(11):1301-2.
Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CK, Edelweiss M, De Mattos-Arruda L, Wen HY, Rakha EA, Ellis IO, Rubin BP, Weigelt B, Reis-Filho JS. Histopathology. 2015 PMID: 25688711.
Brief fixation and hormone receptor expression in breast cancer. Lee AH, Rakha EA, Ellis IO. Am J Surg Pathol. 2015 Mar;39(3):425.
Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer. Abdel-Fatah TM, Ball G, Lee AH, Pinder S, MacMilan RD, Cornford E, Moseley PM, Silverman R, Price J, Latham B, Palmer D, Chan A, Ellis IO, Chan SY. Clin Cancer Res. 2015 Mar 1;21(5):1052-62.
Updated UK Recommendations for HER2 assessment in breast cancer. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology. J Clin Pathol. 2015 Feb;68(2):93-9.
Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, van Deurzen CH, Purnell D, Dodwell D, Chan T, Ellis IO. Br J Cancer. 2015 Jan 20;112(2):283-9.
High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. Rakha EA, Varga Z, Elsheik S, Ellis IO. Histopathology. 2015 Apr;66(5):740-6.
Papillary and neuroendocrine breast lesions: the WHO stance. Tan PH, Schnitt SJ, van de Vijver MJ, Ellis IO, Lakhani SR. Histopathology. 2015 May;66(6):761-70.
VEGF/FGF-dependent vasculogenic mimicry and tumour-derived angiogenic response in high grade glioma. Smith SJ, Ward JH, Tan C, Grundy RG, Rahman R. Oncotarget (advance online June 2015).
microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. Lourdusamy A, Rahman R, Smith SJ Grundy R. Acta Neuropathologica Communications 3: 26 (2015).
Expression alterations define unique molecular characteristics of spinal ependymomas. Lourdusamy A, Rahman R, Grundy R. Oncotarget (2015).
The pioneer factor PBX1 is a novel driver of metastatic progression in ERa-positive breast cancer. Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, Page K, Guttery D, Primrose L, Fernandez Garcia D, Shaw J, Viola P, Green A, Nolan C, Ellis IO, Rakha EA, Shousha S, Lam EW, Gyorffy B, Lupien M, Coombes RC. Oncotarget. 2015 Sep 8;6(26):21878-9.
mELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Herrmann D, Salomon R, Young AI, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JR, Rabinovich B, Millar EK, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole S, Green AR, Timpson P, Gee JM, Ellis IO, Clark SJ, Ormandy CJ. PLoS Biol. 2015 Dec 30;13(12):e1002330.
DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Abdel-Fatah TM, Arora A, Moseley PM, Perry C, Rakha EA, Green AR, Chan SY, Ellis IO, Madhusudan S. Oncotarget. 2015 Sep 8;6(26):21964-78.
Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. Laurinavicius A, Green AR, Laurinaviciene A, Smailyte G, Ostapenko V, Meskauskas R, Ellis IO. Oncotarget. 2015 Dec 1;6(38):41134-45.
KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA. Br J Cancer. 2015 Jun 9;112(12):1929-37.
Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Aleskandarany MA, Soria D, Green AR, Nolan C, Diez-Rodriguez M, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2015 Jun;151(2):325-33.
FKBPL: a marker of good prognosis in breast cancer. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Oncotarget. 2015 May 20;6(14):12209-23.
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, Behnke ML, Huang W, McKew JC, Chernoff J, Forrest WF, Haverty PM, Chin SF, Rakha EA, Green AR, Ellis IO, Caldas C,
O'Brien T, Friedman LS, Koeppen H, Rudolph J, Hoeflich KP. Breast Cancer Res. 2015 Apr 23;17:59.
Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Abduljabbar R, Al-Kaabi MM, Negm OH, Jerjees D, Muftah AA, Mukherjee A, Lai CF, Buluwela L, Ali S, Tighe PJ, Green A, Ellis I, Rakha E. Breast Cancer Res Treat. 2015 Apr;150(3):511-22.
Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green AR, Ali S, Rakha EA, Ellis IO. Breast Cancer Res Treat. 2015 Apr;150(2):335-46.
The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Jerjees DA, Negm OH, Alabdullah ML, Mirza S, Alkaabi M, Hameed MR, Abduljabbar R, Muftah A, Nolan CC, Green AR, Tighe PJ, Band V, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2015 Feb;150(1):91-103.
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR. Breast Cancer Res Treat. 2015 Feb;150(1):81-90.
Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Al-Kaabi MM, Alshareeda AT, Jerjees DA, Muftah AA, Green AR, Alsubhi NH, Nolan CC, Chan S, Cornford E, Madhusudan S, Ellis IO, Rakha EA. Br J Cancer. 2015 Mar 3;112(5):901-11.
Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Moseley PM, Aleskandarany MA, Green AR, Ball G, Alshareeda AT, Rakha EA, Chan SY, Ellis IO, Madhusudan S. Mol Cancer Ther. 2015 Apr;14(4):1057-65.
Biological and clinical significance of PARP1 protein expression in breast cancer. Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2015 Jan;149(2):353-62.
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S. Mol Oncol. 2015 Mar;9(3):569-85.
The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG. J Cancer Res Clin Oncol. 2015 Mar;141(3):505-14.
Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, Rakha EA, Green A, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S. Mol Oncol. 2015 Jan;9(1):204-17.
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G. (2015) Oncogene. 2015 Apr 16;34(16):2103-14.
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C. Mol Oncol. 2015 Jan;9(1):115-27.
Proton pump inhibitors for the treatment of cancer in companion animals. Walsh M, Fais S, Spugnini EP, Harguindey S, Abu Izneid T, Scacco L, Williams P, Allegrucci C, Rauch C, Omran Z. J Exp Clin Cancer Res. 2015 Sep 4;34:93. doi: 10.1186/s13046-015-0204-z. PMID: 26337905.
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Drug Resist Updat. 2015 Nov;23:69-78.
Proton pump inhibitors for the treatment of cancer in companion animals. Walsh M, Fais S, Spugnini EP, Harguindey S, Abu Izneid T, Scacco L, Williams P, Allegrucci C, Rauch C, Omran Z. J Exp Clin Cancer Res. 2015 Sep 4;34:93.
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Cancer Cell Int. 2015 Jul 15;15:71.
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP. Oncotarget. 2015 Nov 3;6(34):35710-25. doi: 10.18632/oncotarget.5958. PubMed PMID: 26461474; PubMed Central PMCID:PMC4742136.
Androgen insensitivity syndrome. Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA. Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):569-80. doi:10.1016/j.beem.2015.04.005. Epub 2015 Apr 26. Review. PubMed PMID: 26303084.
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Sibbesen NA, Kopp KL, Litvinov IV, Jønson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Iversen L, Bonefeld CM, Geisler C, Woetmann A, Odum N. Oncotarget. 2015 Aug 21;6(24):20555-69. PubMed PMID: 26244872; PubMed Central
PMCID: PMC4653025.
Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL. Exp Hematol. 2015 Sep;43(9):781-93.e2. doi: 10.1016/j.exphem.2015.04.012. Epub 2015 May 16. PubMed PMID: 25986473.
Regulation of vascular endothelial growth factor in prostate cancer. de Brot S, Ntekim A, Cardenas R, James V, Allegrucci C, Heery DM, Bates DO, Ødum N, Persson JL, Mongan NP. Endocr Relat Cancer. 2015 Jun;22(3):R107-23. doi:10.1530/ERC-15-0123. Epub 2015 Apr 13. Review. PubMed PMID: 25870249.
Understanding mechanisms of disease development: next generation pathology? Cobb M, Mongan N. Vet J. 2015 Apr;204(1):1-2. doi:10.1016/j.tvjl.2015.03.011. Epub 2015 Mar 16. PubMed PMID: 25841901.
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel JF, Jouet JP, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. JAMA. 2015 Dec 15;314(23):2524-34. doi: 10.1001/jama.2015.16700. PubMed PMID: 26670970.
Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. Arrieta-Bolaños E, Mayor NP, Marsh SG, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, Shaw BE. Haematologica. 2016 Mar;101(3):382-90. doi: 10.3324/haematol.2015.134999. Epub 2015 Nov 26. PubMed PMID: 26611472; PubMed Central PMCID: PMC4815730.
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V. Br J Haematol. 2016 Feb;172(3):360-70. doi: 10.1111/bjh.13802. Epub 2015 Nov 18. PubMed PMID: 26577457.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Lancet Oncol. 2015
Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14. PubMed PMID: 26384238.
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huyn A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2015 Nov;50(11):1411-5. doi: 10.1038/bmt.2015.180. Epub 2015 Sep 14. PubMed PMID: 26367237.
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M. Biol Blood Marrow Transplant. 2016 Feb;22(2):385-90. doi: 10.1016/j.bbmt.2015.09.004. Epub 2015 Sep 9. PubMed PMID: 26363443; PubMed Central PMCID: PMC4728172.
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. J
Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17. PubMed PMID: 26282654.
Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, Craddock C; British Committee for Standards in Haematology. Br J Haematol. 2015 Aug;170(4):487-95. doi: 10.1111/bjh.13554. Epub 2015 Jun 17. PubMed PMID:26081614.
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts. Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK, Hills RK. Br J Haematol. 2015 Jul;170(1):80-4. doi: 10.1111/bjh.13398. Epub 2015 Apr 14. PubMed PMID: 25876768.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group. Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1. PubMed PMID: 25833957; PubMed Central PMCID: PMC4505010.
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK. Blood. 2015 May 7;125(19):2923-32. doi:10.1182/blood-2014-10-608117. Epub 2015 Mar 24. PubMed PMID: 25805811; PubMed Central PMCID: PMC4536889.
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. Horstmann K, Boumendil A, Finke J, Finel H, Kanfer E, Milone G, Russell N, Bacigalupo A, Chalandon Y, Diez-Martin JL, Ifrah N, Chacon MJ, Dreger P. Bone Marrow Transplant. 2015 Jun;50(6):790-4. doi: 10.1038/bmt.2015.12. Epub 2015 Mar 9. PubMed PMID: 25751644.
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D. Leukemia. 2015 Jun;29(6):1312-9. doi: 10.1038/leu.2015.38. Epub 2015 Feb 13. PubMed PMID: 25676423.
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M.
Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19. PubMed PMID: 25527562; PubMed Central PMCID: PMC4349279.
Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation. Truelove E, Fox C, Robinson S, Pearce R, Perry J, Kirkland K, McQuaker G, Pagliuca A, Johnson P, Russell N, Cook G; British Society for Blood and Marrow Transplantation (BSBMT). Biol Blood Marrow
Transplant. 2015 Mar;21(3):483-8. doi: 10.1016/j.bbmt.2014.11.673. Epub 2014 Dec 6. PubMed PMID: 25490180.
Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C, Freeman SD. Leukemia. 2015 Apr;29(4):988-91. doi: 10.1038/leu.2014.327. Epub 2014 Nov 26. PubMed PMID: 25425198;
PubMed Central PMCID: PMC4391965.
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N. Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10.
PubMed PMID: 25387088.
A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Russell NH, Kjeldsen L, Craddock C, Pagliuca A, Yin JA, Clark RE, Howman A, Hills RK, Burnett AK; UK NCRI Adult AML Working Party. Leukemia. 2015 Jul;29(7):1478-84. doi: 10.1038/leu.2014.319. Epub 2014 Nov 7. PubMed PMID: 25376374.
Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. Shaw BE, Lee F, Krishnamurthy S, Byrne JL, Seedhouse C, Mayor NP, Maldonado-Torres H, Saudemont A, Marsh SG, Madrigal JA, Russell NH. Bone Marrow Transplant. 2015 Feb;50(2):237-43. doi: 10.1038/bmt.2014.238. Epub 2014 Oct 27. PubMed PMID: 25347010.
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study. Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C. Bone Marrow Transplant. 2015 Jan;50(1):82-6. doi: 10.1038/bmt.2014.215. Epub 2014 Oct 6. PubMed PMID: 25285801.
Era by era improvement in survival for elderly patients with Hodgkins lymphoma: outcome data from a large population based cohort. Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, Sovani V, Bessell EM, Haynes AP, McMillan AK, Fox CP. Ann Oncol 2015 in press PMID 26374286.
Patients attitudes to risk in lung cancer surgery: a qualitative study. Powell HA, Jones LL, Baldwon DR, Duffy JP, Hubbard RB, Tod AM, Tata LJ, Solomon J, Bains M. Lung Cancer 2015 PMID 26323214.
Variations in lung cancer resources and workload: results from the first national lung cancer organisational audit. Cusworth K, O’Dowd E, Hubbard R, Beckett P, Peake MD. Woolhouse I. Thorax 2015 in press.
Demographics, management, and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD. Lung Cancer 2015 in press. PMID 25863904.
Non-small cell lung cancer in young adults: presentations and survivial in the English National Lung Cancer Audit. Rich AL, Khakwani A, Free CM, Tata LJ, Stanley RA, Peake MD, Hubbard RB, Baldwin DR. QJM 2015 PMID 25725079.
Prevalence of smoking among patients treated in NHS hospitals in England 2010/2011: a national audit. Szatkowski L, Murray R, Hubbard R, Agrawal S, Huang Y, Britton J. Thorax 2015;70:498-500.
What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK. O’Dowd EL, McKeenver TM, Balwdin DR, Anwar S, Powell HA, Gibson JE, Iyen-Omoforman B, Hubbard RB. 2015;70:161-8. The impact of the “hub and Spoke” model of care for lung cancer and equitable access to surgery. Khakwani A, Rich AL, Powell HA, Tata LJ, Stanley RA Baldwin DR, Duffy JP, Hubbard RB. Thorax 2015;70:146-51.
Transcriptomic and protein expression analysis reveals clinicopathological significance of Bloom’s syndrome helicase (BLM) in breast cancer. Arora A, Abdel-Fatah TMA, Agarwal D, Doherty R, Moseley PM, Aleskanadarany MA, Green A, Ball S, Alshareeda AT, Rakha E, Chan SYT, Ellis IO and Madhusudan S. Molecular Cancer Therapeutics. 2015 Apr;14(4):1057-65. DOI: 10.1158/1535-7163.MCT-14-0939.
DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Abdel-Fatah TMA, Arora A, Moseley PM, Perry C, Doherty R, Rakha EA, Green AR, Chan SYT, Ellis IO and Madhusudan S. Oncotarget. 2015 Sep 8;6(26):21964-78.
5-carboxylcytosine levels are elevated in human breast cancers and gliomas Clinical Epigenetics. Eleftheriou M, Jimenez A, Wheldon LM, Perry C, Abakir A, Arora A, Madhusudan S, Ruzov A. 2015. 7(1):88. doi: 10.1186/s13148-015-0117-x. eCollection 2015. (*= joint corresponding authors).
DNA repair endonucleases: Physiological Roles and Potential as Drug Targets. Doherty R and Madhusudan S. Journal of Biomolecular Screening. 2015. Apr 15. pii: 1087057115581581.
Transcriptomic Profiling of Forkhead Box Transcription Factors in Adult Glioblastoma Multiforme. Robertson E, Perry C, Doherty R and Madhusudan S. Cancer Genomics & Proteomics. 2015. 12(3):103-112.
Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer playing a role in chemotherapy response. Al-kaabi MM, Alshareeda AT, Jerjees DA, Abdelhadi Muftah AA, Green AR, Alsubhi N, Nolan C, Chan S, Cornford E, Madhusudan S, Ellis IO, Rakha EA. British Journal of Cancer. 2015 Feb 17. doi: 10.1038/bjc.2014.576.
Monoclonal Antibodies Targeting LecLex -Related Glycans with Potent Anti-tumor Activity. Chua JX, Vankemmelbeke M, McIntosh R, Clarke PA, Moss R, Parsons T, Spendlove I, Zaitoun AM, Madhusudan S and Durrant LG. Clinical Cancer Research. 2015. doi: 10.1158/1078-0432.CCR-14-3030.
Randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin & gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC); the ABC-03 study. Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Duggan M, Cunningham DC, Anthoney A, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA. Lancet Oncology, 2015. pii: S1470-2045(15)00139-4. doi: 10.1016/S1470-2045(15)00139-4.
KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Alshareeda AT, Negm OH, Green AR, Nolan C, Tighe P, Albarakati N, Sultana R , Madhusudan S, Ellis IO, Rakha EA. British Journal of Cancer. 2015. doi: 10.1038/bjc.2015.165.
The Impact of Sarcopenia and Myosteatosis on Outcomes of Unresectable Pancreatic Cancer and Distal Cholangiocarcinoma. Rollins K, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, Fearon KCH, Lobo DN. Clinical Nutrition. 2015. pii: S0261-5614(15)00226-5. doi: 10.1016/j.clnu.2015.08.005.
Multiple pathways regulate Cten in colorectal cancer without a Tensin switch. H Thorpe, M Akhlaq, D Jackson, S Al Ghamdi, S Storr, S Martin M Ilyas. International Journal of Experimental Pathology. (2015) 96(6):362-9.
Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. X Pu, SJ Storr, NS Ahmad, SY Chan, PM Moseley, D Televantou, N Cresti, A Boddy, IO Ellis and SG Martin. Histopathology (2015) Oct 25. doi: 10.1111/his.12896. [Epub ahead of print] PMID: 26496999.
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. N Alsubhi, F Middleton, TMA Abdel-Fatah, P Stephens, R Doherty, A Arora, PM Moseley, SYT Chan, MA Aleskandarany, AR Green, EA Rakha, IO Ellis, SG Martin, NJ Curtin, S Madhusudan. Molecular Oncology. (2015) 10(2):213-23.
Nanoparticles for diagnostic imaging and radiotherapy. KM Prise and SG Martin. British Journal of Radiology. (2015) 88(1054).
Calpain in breast cancer: role in disease progression and treatment response. Sarah J. Storr, Nicola Thompson, Xuan Pu, Yimin Zhang, Stewart G. Martin. Pathobiology. (2015) 82(3-4):133-41.
FKBPL: a marker of good prognosis in breast cancer. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Oncotarget. 2015 May 20;6(14):12209-23.
Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Rea D, Francis A, Hanby AM, Speirs V, Rakha E, Shaaban A, Chan S, Vinnicombe S, Ellis IO, Martin SG, Jones LJ, Berditchevski F; UK Inflammatory Breast Cancer Working group. Br J Cancer. 2015 Apr 28;112(9):1613-5.
Lymphovascular invasion: assessment and prognostic impact in melanoma and breast cancer. Thompson N, Storr S, Zhang S, Martin S. Histol Histopathol. 2015 Sep;30(9):1001-9.
Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication. Perry C, Soomro I, Kaye P, Hardy E, Parsons SL, Ragunath K, Lobo DN, Martin SG, Madhusudan S. Dis Esophagus. 2015 Apr;28(3):262-8.
Mitotic activity of survivin is regulated by acetylation at K129. Aljaberi AM, Webster JR, Wheatley SP. Cell Cycle. 2015;14(11):1738-47. doi: 10.1080/15384101.2015.1033597.
The functional repertoire of survivin's tails. Wheatley SP. Cell Cycle. 2015;14(2):261-8. doi: 10.4161/15384101.2014.979680.
Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1. Jadhav, G.P., Kaur, I., Maryati, M., Airhihen, B., Fischer, P.M., and Winkler, G.S. (2015) Bioorganic and Medicinal Chemistry Letters, 25, 4219-4224.
Asymmetric Copper-Catalyzed Addition of ZnEt2 to Pentafulvenes. M. Cini, TD Bradshaw, S Woodward and W Lewis. Angew. Chem. Int. Ed. 2015, 54, 14179-14182.
N3-Substituted temozolomide analogues overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. J Zhang, M Hummersone, C S Matthews, MFG Stevens, TD Bradshaw. Oncology 2015, 88, 28-48.
In vitro anti-tumour mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl) methanesulfonamide. Tiangong Lu, Charles A Laughton, Shudong Wang, Tracey D Bradshaw. Molecular Pharmacology, 2015, 87, 18-30.
Ibogan, Tacaman, and Cytotoxic Bisindole Alkaloids from Tabernaemontana. Cononusine, an Iboga Alkaloid with Unusual Incorporation of a Pyrrolidone Moiety. Kuan-Hon Lim, Vijay J. Raja, Tracey D. Bradshaw, Siew-Huah Lim, Yun-Yee Low, and Toh-Seok Kam. J. Nat. Prod., 2015, 78 (5), pp 1129–1138. Publication Date (Web): April 28, 2015 (Article). DOI: 10.1021/acs.jnatprod.5b00117.
Asymmetric Pentafulvene Carbometallation – Access to Enantiopure Titanocene Dichlorides of Biological Relevance. Melchior Cini, Tracey D Bradshaw, Simon Woodward and W. Lewis. Angew. Chemie 2015, 54 (47), 14179-14182.
An apoferritin based drug delivery system for the tyrosine kinase inhibitor Gefitinib. Anchala I. Kuruppu, Lei Zhang, Hilary Collins, Lyudmila Turyanska, Neil R. Thomas and Tracey D. Bradshaw. Advanced Healthcare Materials, 2015 4 (18) 2816-2821; DOI 10.1001/adhm.201500389.
Antitumour Benzothiazoles 32. D DNA adducts and double strand breaks correlate with activity; synthesis of 5F 203 hydrogels for local delivery. EL Stone, F Citossi, R Singh, B Kaur, M Gaskell, P B Farmer, A Monks, C Hose, MFG Stevens, C-O Leong, M Stocks, B Kellam, M Marlow and TD Bradshaw. Bioorganic & Medicinal Chemistry 2015, 23, 6891-6899.
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Zhang W, Yu Y, Hertwig F, et al. Genome biology 2015; 16: 133.
A Common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. Somers J, Wilson LA, Kilday JP, et al. Genes and Development 2015 Sep 15; 29(18):1891-6.
The UK experience of a treatment strategy for pediatric metastatic medulloblastoma comprising intensive induction chemotherapy, hyperfractionated accelerated radiotherapy and response directed high dose myeloablative chemotherapy or maintenance chemotherapy (Milan Strategy). Vivekanandan S, Breene R, Ramanujachar R, et al. Pediatic Blood Cancer 2015; 62(12): 2132-9.
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Torchia J, Picard D, Lafay-Cousin L, et al. Lancet Oncol 2015; 16(5): 569-82.
Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response. Smith SJ, Ward JH, Tan C, Grundy RG, Rahman R. Oncotarget 2015.
Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Shlien A, Campbell BB, de Borja R, et al. Nat Genet 2015; 47(3): 257-62.
microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. Lourdusamy A, Rahman R, Smith S, Grundy R. Acta neuropathologica communications 2015; 3: 26.
Expression alterations define unique molecular characteristics of spinal ependymomas. Lourdusamy A, Rahman R, Grundy RG. Oncotarget 2015.
In vitro co-culture model of medulloblastoma and human neural stem cells for drug delivery assessment. Ivanov DP, Parker TL, Walker DA, et al. Journal of biotechnology 2015.
Multi-centre reproducibility of diffusion MRI parameters for clinical sequences in the brain. Grech-Sollars M, Hales PW, Miyazaki K, et al. NMR Biomed 2015; 28(4): 468-85.
3D Texture Analysis of Heterogeneous MRI Data for Diagnostic Classification of Childhood Brain Tumours. Fetit AE, Novak J, Rodriguez D, et al. Studies in health technology and informatics 2015; 213: 19-22.
ABCB1 in children's brain tumours. Coyle B, Kessler M, Sabnis D, Kerr ID. Biochem Soc Trans 2015; 43(5): 1018-22.
Pattern of symptoms and signs of primary intracranial tumours in children and young adults: a record linkage study. Chu TP, Shah A, Walker D, Coleman MP. Arch Dis Child 2015.
Highlights | 2016 | 2015 | 2014 | 2013 | 2012 | Archived